8-K: LivaNova Raises Guidance on Strong Q2 Revenue Growth

LivaNova PLC reported robust second-quarter 2026 financial results, exceeding revenue expectations and prompting an increase in full-year guidance, alongside a significant supply chain agreement.

Summary

• LivaNova PLC announced strong financial results for the second quarter ended June 30, 2026.
• Total revenue for the quarter was $390.6 million, an increase of 10.8% on a reported basis and 9.8% on a constant-currency basis compared to the prior year.
• The company raised its full-year 2026 revenue growth guidance to 8%-9% on a constant-currency basis and increased its adjusted diluted earnings per share (EPS) guidance to $4.30-$4.40.
• A favorable ruling from the Italian tax authority resulted in a discrete tax benefit of $95.4 million.
• The company entered into a long-term agreement with Thermo Fisher Scientific to enhance oxygenator component supply.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with the company exceeding revenue expectations and raising full-year guidance, alongside a strategic supply chain agreement.

Positives

• Reported double-digit reported revenue growth of 10.8% in Q2 2026.
• Achieved constant-currency revenue growth of 9.8% in Q2 2026.
• Raised full-year 2026 revenue growth guidance by 100 basis points to 8%-9% on a constant-currency basis.
• Increased full-year 2026 adjusted diluted EPS guidance by $0.10 at the midpoint to $4.30-$4.40.
• Secured a long-term agreement with Thermo Fisher Scientific to strengthen oxygenator component supply.
• Announced positive data for PolySync programming algorithm showing an 84.5% cumulative apnea-hypopnea index response rate.
• Received a favorable ruling from the Italian tax authority, recognizing a discrete tax benefit of $95.4 million.

Negatives

• Lowered full-year 2026 adjusted free cash flow range to $140 million to $160 million from a previous range of $160 million to $180 million.
• GAAP operating income decreased to $49.5 million in Q2 2026 from $54.2 million in Q2 2025, although adjusted operating income increased.

Risks

• Risks associated with doing business globally, including market volatility and economic conditions.
• Adverse changes in export/import costs, trade restrictions, and global tariffs.
• Supply chain pressures and potential disruptions.
• Failure to protect or upgrade IT systems, or safeguard against cybersecurity incidents.
• Costs associated with complying with privacy and security laws.
• Changes in technology and competition from alternative medical therapies.
• Risks related to AI integration and regulation.
• Failure of investments, alliances, or acquisitions to achieve expected returns.

Future Outlook

Full-year 2026 revenue is now expected to grow between 8% and 9% on a constant-currency basis. Full-year 2026 adjusted diluted EPS is projected to be in the range of $4.30 to $4.40. Adjusted free cash flow for 2026 is now estimated to be between $140 million and $160 million.

Management Comments

• "In the second quarter, LivaNova delivered strong revenue growth driven by sustained performance in our Cardiopulmonary and Epilepsy businesses," said Vladimir Makatsaria, Chief Executive Officer of LivaNova.
• "We are also pleased to announce an agreement with Thermo Fisher Scientific, an important step in securing a critical component for our oxygenators, supporting the Cardiopulmonary supply chain long-term."
• "Our updated 2026 guidance reflects strong execution in the core businesses as we advance our strategic plan and drive long-term value creation."

Industry Context

StockSavvy.ai notes that LivaNova's performance aligns with a trend of recovery and growth in the medical technology sector, particularly for companies focused on specialized devices and therapies. The agreement with Thermo Fisher Scientific highlights the industry's focus on securing critical component supply chains to meet increasing demand.

Management Changes

Legal Proceedings

• Ongoing legal expenses related to 3T Heater-Cooler defense and litigation provision.
• Saluggia site remediation provision and related legal costs.
• Potential impact from environmental laws and regulations, including liabilities and litigation.

Stakeholder Impact

• Shareholders: Positive impact from raised guidance and strong revenue growth, potentially leading to increased stock value.
• Customers: Potential for improved product availability (oxygenators) due to the Thermo Fisher Scientific agreement, helping to satisfy unmet demand.
• Employees: Continued focus on talent retention and execution of strategic plans.
• Suppliers: Strengthened relationship with Thermo Fisher Scientific for critical components.

Next Steps

• Continue to execute on the strategic plan to drive long-term value creation.
• Leverage the agreement with Thermo Fisher Scientific to increase oxygenator output and satisfy unmet demand.
• Further develop and commercialize the PolySync programming algorithm for Obstructive Sleep Apnea therapy.
• Monitor and manage supply chain dynamics for critical components.

Key Dates

Recommendation

The company demonstrated strong Q2 performance and raised guidance, which is positive. However, the reduction in free cash flow guidance and ongoing legal/environmental provisions warrant a cautious approach. A 'hold' recommendation reflects the balance between positive operational execution and existing risks.

Keywords

medical technology, revenue growth, earnings per share, guidance, oxygenator, supply chain, Cardiopulmonary, Neuromodulation